Sumit Madan, MD
Hematology & Oncology · Gilbert, AZNPI 1972766756
Payments from drug & device makers
Across 850 payments — averaging $8359.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Beigene, Ltd.$4.1M
- Janssen Research & Development, LLC$914K
- Beone Medicines Ltd.$523K
- Karyopharm Therapeutics Inc.$427K
- Pfizer$336K
- Sanofi US Services Inc.$153K
- plus $691K from 25 others
Across 9 payments — averaging $383.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$3K
- Pfizer$950
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Beigene, Ltd. | 217 | $4,062,120 |
| Janssen Research & Development, LLC | 43 | $913,711 |
| Beone Medicines Ltd. | 29 | $522,998 |
| Karyopharm Therapeutics Inc. | 104 | $426,513 |
| Pfizer | 35 | $336,022 |
| Sanofi US Services Inc. | 22 | $152,561 |
| Johnson & Johnson | 130 | $130,072 |
| Merck | 9 | $128,492 |
| Takeda Pharmaceuticals U.S.A., Inc. | 57 | $124,044 |
| AstraZeneca | 11 | $95,925 |
| Bristol Myers Squibb | 78 | $76,991 |
| Beigene USA, Inc. | 1 | $41,782 |
| Amgen | 46 | $41,131 |
| Sanofi | 29 | $22,396 |
| GSK | 12 | $20,283 |
| Janssen Scientific Affairs, LLC | 7 | $7,836 |
| AbbVie | 1 | $1,375 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $167 |
| Genmab U.S., Inc. | 1 | $124 |
| Seagen Inc. | 1 | $122 |
| Dova Pharmaceuticals | 1 | $109 |
| E.r. Squibb & Sons, L.L.C. | 1 | $99 |
| Legend Biotech USA Inc. | 1 | $74 |
| Sanofi-aventis U.S. LLC | 2 | $63 |
| Tesaro, Inc. | 1 | $59 |
| Daiichi Sankyo Inc. | 2 | $28 |
| Astellas Pharma US Inc | 2 | $25 |
| Incyte Corporation | 1 | $20 |
| Puma Biotechnology, Inc. | 1 | $19 |
| Coherus Oncology, Inc. | 1 | $13 |
| Gilead | 1 | $12 |
How this compares
$7,105,188 in reported general payments places this provider in the 95th percentile of 261 hematology & oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Gilbert
- Jiaxin NiuGilbert$10.7M
- Hung KhongGilbert$2.8M
- Matthew UlricksonGilbert$1.9M
- Lida MinaGilbert$1.8M
- Horst KlueppelbergGilbert$607K
- Yazan SamhouriGilbert$592K
- Qing ZhaoGilbert$582K
- Tanios Bekaii-SaabScottsdale$31.4M
- Yousef ZakhariaScottsdale$13M
- Sudhir MandaTucson$10M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.